BreezeMeds Review

BreezeMeds is a cash-pay telehealth storefront for compounded GLP-1 weight management and selected prescription longevity products. Its embedded privacy policy names Breezemeds, LLC, a Delaware corporation at a Marietta, Georgia address. The footer separately says Breezemeds, Inc., so the exact legal suffix should be confirmed in the patient's agreement.

The platform relationship is clearer than the storefront entity relationship. BreezeMeds links checkout users to CareGLP terms. Those terms say CareValidate supplies administrative and technology services, independent professional entities provide medical care, and independent pharmacies and laboratories perform fulfillment and testing.

The main FAQ identifies Lion MD and names Ana Lisa Carr, MD, and Kelly Tenbrink, MD. Both NPIs are active in the federal NPI Registry. Dr. Carr's record lists family medicine and a California license, while Dr. Tenbrink's record lists emergency medicine and a Tennessee license. These records verify identity, not assignment or every state license.

CareGLP terms separately say medical services are provided through independent providers and Usable Health, PC. The public pages do not explain whether Lion MD and Usable Health handle different products, states, or administrative roles. A patient should obtain the assigned clinician's full name, professional entity, role, and active license for the patient's state.

BreezeMeds names Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx. Naming partners adds useful context, but no public page maps one pharmacy to a particular medication, formulation, or state. Confirm the dispensing pharmacy, license, formulation, concentration, storage, and testing before the prescription is filled.

The care path starts with an online questionnaire, followed by medical consultation, a prescribing decision, delivery when treatment is approved, and ongoing support. Checkout explicitly says a prescription is not guaranteed and payment is not processed until approval. The exact consultation format and timing can vary by product.

The current checkout-linked product configuration lists compounded semaglutide injection at $199 for one month, $748 for three months, $1,248 for six months, and $2,298 for twelve. The longest total averages $191.50 per stated month, shown as a compact $192 card. The three-month plan averages more than the one-month price, so quantity and billing terms require confirmation.

Compounded tirzepatide injection is configured at $299 for one month, $1,068 for three months, $1,918 for six months, and $3,498 for twelve. The longest total averages $291.50, shown as $292. The homepage still says tirzepatide starts at $399, while checkout treats $399 as the crossed-out comparison price.

Checkout warns that prices are based on the lowest dosage rates and that higher dosages may cost more. It displays total-if-prescribed amounts, but public pages do not explain all dose tiers, medication quantities, later charge dates, or how multi-month totals interact with cancel-anytime marketing and completed-sale finality.

The site lists compounded oral semaglutide at $299 monthly and oral tirzepatide at $399, with longer plan totals. They remain editorial-only route variants under the same active ingredients, not extra medication cards. Neither is an FDA-approved oral finished product equivalent to approved semaglutide or tirzepatide injections. Confirm the pharmacy, ingredient form, absorption evidence, dose, and monitoring plan.

NAD+ pricing is internally inconsistent. The homepage and current product configuration say $169 monthly, the NAD+ hero says $179 to start, and the NAD+ FAQ calls $249 the regular price. The review uses $169 because it is the current checkout-linked configuration, but readers should confirm the amount and recurring charge.

BreezeMeds also lists NAD+ nasal spray at $210. It stays in the editorial notes because it is a route variant under NAD+, not a new active ingredient. The public pages do not publish enough formulation, dose, quantity, absorption, or comparative evidence to rank injection and nasal spray as interchangeable offers.

NAD+ has biological roles, but those roles do not prove advertised energy, cognition, skin, or anti-aging outcomes for a compounded prescription. FDA has received adverse-event reports after compounded NAD+ injections and has warned compounders about ingredient suitability and endotoxin risk in sterile production.

Sermorelin is $135 in the current product configuration but $100 on the NAD+ therapy card. The $135 value is used because it is linked to checkout. Sermorelin should be treated as a compounded prescription with an individualized rationale, baseline evaluation, monitoring, and measurable goal, not as a generally proven anti-aging product.

Compounded products are not FDA approved and are not reviewed before marketing for safety, effectiveness, or quality. Ingredient normalization does not establish equivalence to an approved finished product. Patients should confirm the ingredient form, concentration, additives, prescribed milligrams, syringe units, beyond-use date, storage, testing, and patient-specific reason for compounding.

The cancellation language needs care. Checkout and the NAD+ page say patients can cancel or change anytime and advertise no commitments or cancellation fees. CareGLP terms say medical consultation fees are generally nonrefundable and prescription sales are final. The separate refund policy permits narrow error, damage, and pre-fill cancellation exceptions.

The separate refund policy says appointment cancellation at least twenty-four hours in advance incurs no charge. A later cancellation may incur $80. If the clinician decides after the appointment that GLP-1 treatment is not appropriate, the policy says the patient is charged $80 for a video consult or $70 for a phone consult.

Availability also conflicts. BreezeMeds says it services all fifty states. CareGLP terms say services are available only in certain states and direct users to support for the current list. Verify the medication, formulation, clinician license, pharmacy, and final price for the patient's location rather than relying on the broad homepage statement.

The main FAQ estimates two to three weeks from consultation through delivery. The NAD+ page separately says review can occur within two to four hours and that most patients receive NAD+ in three to five business days. Neither is a guarantee, and CareGLP terms disclaim responsibility for third-party pharmacy and carrier delays.

Support routes include support@breezemeds.com, platform messaging, and provider marketing for ongoing or unlimited 24/7 help. No public general telephone number, service hours, response-time commitment, or definition of after-hours clinical coverage was found. Administrative availability should not be treated as continuous clinician access.

CareGLP publishes recommended laboratory categories for many adults using GLP-1 treatment, including metabolic, lipid, glycemic, thyroid, blood-count, and vitamin D testing. BreezeMeds does not state which tests are mandatory, included, repeated, or separately billed for each patient and product.

The site is visually polished, but its FAQ data needs repair. The question about costs and insurance displays a two-to-three-week timeline answer. The question about shipping displays a GLP-1 outcome answer. Patient-count marketing also differs between 50,000 and 100,000. These issues do not prove care quality, but they reduce confidence in public-detail maintenance.

Weight-loss and NAD+ outcome claims are provider marketing, not independently verified BreezeMeds results. Approved-drug trial findings cannot be transferred automatically to a compounded formulation, and anecdotal testimonials cannot establish expected benefit. The prescribing clinician should define a realistic, measurable goal and a stop or change plan.